A242 DELAYED STEROID TAPER MAY REDUCE RISK OF RELAPSE IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HEPATOTOXICIT

por Almousawi, F, Butler, M, Bedard, P, Spreafico, A, Siu, L, Cunningham, M
Publicado 2023

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma

por Oliva, M, Spreafico, A, Taberna, M, Alemany, L, Coburn, B, Mesia, R, Siu, L L
Publicado 2019

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)

por Cappuzzo, F, Bartolini, S, Ceresoli, G L, Tamberi, S, Spreafico, A, Lombardo, L, Gregorc, V, Toschi, L, Calandri, C, Villa, E, Crinò, L
Publicado 2004

Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma

por Janku, F., Bauer, S., Shoumariyeh, K., Jones, R.L., Spreafico, A., Jennings, J., Psoinos, C., Meade, J., Ruiz-Soto, R., Chi, P.
Publicado 2022

A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies

por Spreafico, A, Delord, J-P, De Mattos-Arruda, L, Berge, Y, Rodon, J, Cottura, E, Bedard, P L, Akimov, M, Lu, H, Pain, S, Kaag, A, Siu, L L, Cortes, J
Publicado 2015

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors

por Borazanci, E., Schram, A.M., Garralda, E., Brana, I., Vieito Villar, M., Spreafico, A., Oliva, M., Lakhani, N.J., Hoffman, K., Hallett, R.M., Maetzel, D., Hua, F., Hilbert, J., Giblin, P., Anido, J., Kelly, A., Vickers, P.J., Wasserman, R., Seoane, J., Siu, L.L., Hyman, D.M., Hoff, D.V., Tabernero, J.
Publicado 2022